Effectiveness and Pharmacoeconomic Evaluation of Rituximab for Treatment of Non-Hodgkin's Lymphoma

SHI Hao-qiang,SHEN Yang,YE Ying-qiong,ZHANG Fen-qin,TAO Jing,CAI Wei-min
DOI: https://doi.org/10.3969/j.issn.1671-2838.2007.05.010
2007-01-01
Pharmaceutical Care and Research
Abstract:Objective:To elucidate the efficacy and adverse drug reaction of rituximab in treatment of non-Hodgkin's lymphoma.Methods:According to the oversea investigation and research carried out in the department of hematology in Ruijin Hospital,untraditional pharmacoeconomic method was used to evaluate the therapeutic protocol of rituximab.Results:Rituximab plus CHOP chemotherapy(cyclophosphamide,doxorubicin,vincristine and prednisone) had better therapeutic results in the treatment of non-Hodgkin's lymphoma than traditional CHOP chemotherapy alone in the aspect of pharmacoeconomics.Conclusion:Rituximab is a fine and phamacoeconomic choice for non-Hodgkin's lymphoma with satisfactory efficacy and safety.
What problem does this paper attempt to address?